TSHA (Taysha Gene Therapies) Intangible Assets: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSHA Taysha Gene Therapies Inc TSHA
33 GF Score
Price $5.02
GF Value $0.53
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Taysha Gene Therapies Intangible Assets?

Taysha Gene Therapies TSHA -2.71% 33 Intangible Assets is $0.00 Mil as of Jun. 2026. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Taysha Gene Therapies's intangible assets for the quarter that ended in Jun. 2026 was $0.00 Mil.


Taysha Gene Therapies  (NAS:TSHA) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Taysha Gene Therapies Intangible Assets Related Terms


Taysha Gene Therapies Intangible Assets Historical Data

* Premium members only.

The historical data trend for Taysha Gene Therapies's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taysha Gene Therapies Intangible Assets Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Taysha Gene Therapies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSHA
33GF Score
Taysha Gene Therapies Inc TSHA
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taysha Gene Therapies Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of $0.00 Mil mean?
Taysha Gene Therapies (TSHA) has a Intangible Assets of $0.00 Mil as of Jun. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Taysha Gene Therapies and its competitors.
Is Taysha Gene Therapies' Intangible Assets too high?
Taysha Gene Therapies' current Intangible Assets is $0.00 Mil. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Intangible Assets compare to KARD and GHRS?
Taysha Gene Therapies' Intangible Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current Intangible Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current Intangible Assets is $0.00 Mil. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Intangible Assets is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taysha Gene Therapies (TSHA) Overvalued in 2026?

Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued. The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53. GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.

Key valuation signals for TSHA:

  • Intangible Assets: $0.00 Mil
  • GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taysha Gene Therapies Business Description

Address 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score

Get the complete analysis for TSHA

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.53
GF Value